Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Singulex to Present at Piper Jaffray 28th Annual Healthcare Conference

Posted on: 17 Nov 16

PR Newswire

ALAMEDA, Calif., Nov. 17, 2016

ALAMEDA, Calif., Nov. 17, 2016 /PRNewswire/ -- Singulex, Inc., the leader in Next Generation Immunodiagnostics powered by Single Molecule Counting technology, today announced that president and chief executive officer Guido Baechler will present at the 28th Annual Piper Jaffray Healthcare Conference, being held November 29 and 30, 2016 in New York, NY.

Mr. Baechler will provide an overview of the Company and its next generation immunodiagnostics platform powered by proprietary SMC™ technology. Singulex delivers the ability to rule-out disease and support physician, patient and hospital administrator decisions to identify and treat some of the world's costliest diseases. This clinically-proven disease rule-out ability will soon be available to hospitals and reference labs via the Sgx Clarity™ System IVD platform, which is currently in clinical evaluation in Europe with FDA evaluation for the United States planned for 2017, and an extensive pipeline of planned clinical applications using proven biomarkers.

Details of the 28th Annual Piper Jaffray Healthcare Conference presentation are as follows:

Date: November 29, 2016
Time: 1:50 p.m. EST
Location: Lotte New York Palace Hotel, New York, NY

Investors who are interested in meeting with Singulex management may request a meeting by contacting Lee Roth or Joseph Green of The Ruth Group at or

About Singulex, Inc.
Singulex is the next generation immunodiagnostic company. Its proprietary single molecule counting technology, SMC™, enables physicians, laboratorians and scientists to detect biomarkers of disease that were previously undetectable. Powered by SMC technology, Singulex's ultrasensitive lab testing services are transforming patient care from reactive disease treatment to proactive health management. Singulex's Sgx Clarity™ System IVD platform, currently in evaluation and not yet available for sale, is designed to bring SMC power and the ability to definitively rule-out disease to physicians, hospitals and laboratories. For more information, visit


(Media) Luke Dickinson
Burson-Marsteller on behalf of Singulex
T: 202-530-4780
C: 609-577-8721  

(Investors) Lee Roth / Joseph Green
The Ruth Group on behalf of Singulex
T: 646-536-7012 / 7013 /


To view the original version on PR Newswire, visit:

SOURCE Singulex, Inc.

PR Newswire

Last updated on: 17/11/2016

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.